Medicare Enrolled
Dr. Honghao Yang, MD
Optician · Alhambra, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Yang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Yang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Yang
Dr. Honghao Yang is an optician specialist in Alhambra, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Yang performed 19,231 Medicare services across 1,133 unique beneficiaries.
Between the years covered by Open Payments, Dr. Yang received a total of $45,962 from 87 pharmaceutical and/or device companies across 1379 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Yang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 5% volume in CA
$45,962 industry payments
Medicare Practice Summary
Medicare Utilization ↗19,231
Medicare services
Top 5% in CA for optician
1,133
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,012 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 9,660 | $18 | $45 |
| Anti-nausea injection (ondansetron/Zofran) | 4,008 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,046 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,026 | $94 | $271 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
364 | $12 | $30 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
328 | $120 | $299 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
236 | $1 | $2 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
228 | $46 | $193 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
223 | $26 | $65 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
214 | $93 | $140 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
210 | $64 | $193 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
128 | $14 | $34 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
110 | $30 | $70 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
97 | $25 | $61 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
70 | $59 | $145 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
68 | $1 | $16 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
60 | $64 | $153 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
55 | $8 | $13 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
38 | $145 | $389 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
36 | $127 | $361 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
26 | $55 | $148 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.4% high complexity
86.6% medium
10.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$45,962
Total received (2018-2024)
Avg $6,566/year across 7 years
Top 5% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
87
Companies
1,379
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$31,508 (68.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$12,331 (26.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,123 (4.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$6,007
2023
$8,646
2022
$7,737
2021
$9,653
2020
$6,019
2019
$4,862
2018
$3,037
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$721
Novartis Pharmaceuticals Corporation
$446
AstraZeneca Pharmaceuticals LP
$420
SOBI, INC
$290
Lilly USA, LLC
$284
Incyte Corporation
$263
Gilead Sciences, Inc.
$256
PFIZER INC.
$251
GlaxoSmithKline, LLC.
$247
Takeda Pharmaceuticals U.S.A., Inc.
$201
Daiichi Sankyo Inc.
$190
Secura Bio, Inc.
$180
Exelixis Inc.
$168
GENZYME CORPORATION
$154
Merck Sharp & Dohme LLC
$142
Celgene Corporation
$142
Kite Pharma, Inc.
$119
EMD Serono, Inc.
$114
Regeneron Healthcare Solutions, Inc.
$102
ARRAY BIOPHARMA INC
$88
Genentech USA, Inc.
$86
BeiGene USA, Inc.
$82
ABBVIE INC.
$79
Astellas Pharma US Inc
$79
PharmaEssentia USA Corporation
$76
Bayer Healthcare Pharmaceuticals Inc.
$74
Boehringer Ingelheim Pharmaceuticals, Inc.
$73
Stemline Therapeutics Inc.
$69
Genmab U.S., Inc.
$55
E.R. Squibb & Sons, L.L.C.
$49
Alexion Pharmaceuticals, Inc.
$49
Blueprint Medicines Corporation
$48
TAIHO ONCOLOGY, INC.
$46
Ipsen Biopharmaceuticals, Inc
$38
Boston Scientific Corporation
$37
Novocure Inc.
$34
Rigel Pharmaceuticals, Inc.
$31
Karyopharm Therapeutics Inc.
$29
PUMA BIOTECHNOLOGY, INC.
$28
Deciphera Pharmaceuticals Inc.
$28
SpringWorks Therapeutics, Inc.
$27
JAZZ PHARMACEUTICALS INC.
$26
Agios Pharmaceuticals, Inc.
$25
Fennec Pharmaceuticals, Inc.
$23
Coherus Biosciences Inc.
$20
Menarini Silicon Biosystems, Inc.
$16
Top 3 companies account for 26.4% of 2024 payments
All-time payments by company (2018-2024) ›
Eisai Inc.
$6,118
AstraZeneca Pharmaceuticals LP
$3,424
Janssen Biotech, Inc.
$2,950
Exelixis Inc.
$2,720
TAIHO ONCOLOGY, INC.
$2,670
ABBVIE INC.
$2,185
PFIZER INC.
$1,992
Genentech USA, Inc.
$1,848
Lilly USA, LLC
$1,538
Amgen Inc.
$1,439
Novartis Pharmaceuticals Corporation
$1,408
Incyte Corporation
$1,198
GENZYME CORPORATION
$1,162
E.R. Squibb & Sons, L.L.C.
$1,089
Gilead Sciences, Inc.
$1,069
Celgene Corporation
$884
Astellas Pharma US Inc
$855
EMD Serono, Inc.
$734
GlaxoSmithKline, LLC.
$641
Bayer HealthCare Pharmaceuticals Inc.
$635
Takeda Pharmaceuticals U.S.A., Inc.
$598
SOBI, INC
$520
Merck Sharp & Dohme LLC
$438
Pharmacyclics LLC, An AbbVie Company
$431
Daiichi Sankyo Inc.
$421
Alexion Pharmaceuticals, Inc.
$373
Regeneron Healthcare Solutions, Inc.
$353
Merck Sharp & Dohme Corporation
$316
Nestle HealthCare Nutrition Inc.
$301
Dova Pharmaceuticals
$282
Boehringer Ingelheim Pharmaceuticals, Inc.
$280
PharmaEssentia USA Corporation
$271
Stemline Therapeutics Inc.
$271
Kite Pharma, Inc.
$218
Secura Bio, Inc.
$217
Bayer Healthcare Pharmaceuticals Inc.
$215
Deciphera Pharmaceuticals Inc.
$209
Seattle Genetics, Inc.
$201
Jazz Pharmaceuticals Inc.
$196
Pharmacyclics LLC, an AbbVie Company
$190
EISAI INC.
$172
AbbVie Inc.
$165
TESARO, Inc.
$163
Clovis Oncology, Inc.
$153
Seagen Inc.
$151
ARRAY BIOPHARMA INC
$138
Epizyme, Inc.,
$134
Mirati Therapeutics, Inc.
$125
Alnylam Pharmaceuticals Inc.
$122
Verastem, Inc.
$119
Blueprint Medicines Corporation
$107
Puma Biotechnology, Inc.
$103
Teva Pharmaceuticals USA, Inc.
$85
Ipsen Biopharmaceuticals, Inc
$85
BeiGene USA, Inc.
$82
Genmab U.S., Inc.
$80
Taiho Oncology, Inc.
$78
Rigel Pharmaceuticals, Inc.
$76
ADC Therapeutics America, Inc.
$71
Sobi, Inc
$61
NESTLE HEALTHCARE NUTRITION INC.
$54
Karyopharm Therapeutics Inc.
$52
JAZZ PHARMACEUTICALS INC.
$52
AbbVie, Inc.
$47
Aadi Bioscience, Inc.
$47
MEDIVATION FIELD SOLUTIONS LLC
$43
MorphoSys, US Inc.
$38
Boston Scientific Corporation
$37
ImmunoGen, Inc.
$36
Novocure Inc.
$34
MACROGENICS, INC.
$31
Janssen Pharmaceuticals, Inc
$29
PUMA BIOTECHNOLOGY, INC.
$28
SpringWorks Therapeutics, Inc.
$27
Agios Pharmaceuticals, Inc.
$25
Dendreon Pharmaceuticals LLC
$25
Pharmacosmos Therapeutics Inc.
$24
Apellis Pharmaceuticals, Inc.
$23
Fennec Pharmaceuticals, Inc.
$23
Immunomedics, Inc.
$22
CTI BioPharma Corp.
$21
NOVARTIS PHARMACEUTICALS CORPORATION
$20
Coherus Biosciences Inc.
$20
Kyowa Kirin, Inc.
$19
APO-PHARMA USA, INC.
$18
Sun Pharmaceutical Industries Inc.
$17
Menarini Silicon Biosystems, Inc.
$16
Top 3 companies account for 27.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · AUGTYRO · AYVAKIT · Abraxane · Alecensa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · COPIKTRA · CREON · CYRAMZA · Cabometyx · Cellsearch · Copiktra · DARZALEX · DEFERIPRONE · DOPTELET · Doptelet · ELAHERE · ELITEK · ELREXFIO · ELZONRIS · EMEND · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · EXKIVITY · Elahere · Empaveli · Enhertu · Epkinly · Erleada · FARESTON · FRUZAQLA · Fabhalta · Farydak · Fyarro · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INQOVI · Imbruvica · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MARGENZA · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Optune Lua (NovoTTF-200T) · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POLIVY · PROMACTA · PROVENGE · PYRUKYND · Padcev · Pedmark · Perjeta · Polivy · Pomalyst · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SYNAGIS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tecentriq · TheraSphere Y90 Glass Microspheres 10 GBq · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · VPRIV · Vectibix · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (69%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 5% for optician in CA.
Geographic Context
Opticians within 10 mi
1,684
Per 100K population
17.1
County median income
$87,760
Nearest hospital
ALHAMBRA HOSPITAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Yang is a mixed practice specialist, with above-average Medicare volume (top 5% in CA), with low-engagement industry engagement in the top 5% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Yang experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Yang performed 9,660 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Yang receive payments from pharmaceutical companies?
Yes. Dr. Yang received a total of $45,962 from 87 companies across 1,379 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Yang's costs compare to other opticians in Alhambra?
Dr. Yang's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Yang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Alhambra
Browse opticians in Alhambra ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
Eisai Inc. Payments to Doctors
See all physicians who received payments from Eisai Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology